- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06566170
En verklig jämförande studie av Donanemab (LY3002813) plus vanlig vård kontra vanlig vård ensam hos deltagare i USA med tidig symtomatisk Alzheimers sjukdom
Långsiktig verklig jämförande effektivitet av Donanemab Plus vanlig vård kontra vanlig vård ensam hos amerikanska patienter med tidig symtomatisk Alzheimers sjukdom (TRAILBLAZER-REAL US)
The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, observational cohort design with participant management resembling real-world practice to the greatest extent possible via prospective assessments and linkage to historical and prospective electronic health records. The study will last about 273 weeks and may include up to 28 visits.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
- Telefonnummer: 1-317-615-4559
- E-post: clinical_inquiry_hub@lilly.com
Studieorter
-
-
Alabama
-
Huntsville, Alabama, Förenta staterna, 35805-4046
- Rekrytering
- Rehabilitation & Neurological Services
-
Huvudutredare:
- Belinda Savage-Edwards
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
The study population will consist of a donanemab plus usual care group and a usual care alone group. Participants will be enrolled 1:2 into donanemab plus usual care and usual care alone groups to allow enough participants in the usual care group to be matched with participants in the donanemab group to enable robust comparative effectiveness analyses.
Beskrivning
Inclusion Criteria:
Participants
- are under care for presumed mild cognitive impairment (MCI) or mild dementia stage of AD (Note: neither a biomarker-based diagnosis of AD nor a diagnosis in electronic health records [EHR] is required prior to screening)
- have a Telephone Interview for Cognitive Status (TICS) score of ≥21
- presence of amyloid beta (Aβ) pathology supported by biomarker results (e.g., P-tau, amyloid positron emission tomography (PET), and/or cerebrospinal fluid [CSF]). (Note: A historical biomarker may be used for eligibility if performed within 12 months of study entry)
- have a reliable study partner who is in frequent contact with the participant and will be available by telephone at designated times (every 6 months), and
- have EHR data available for linkage and are willing to allow access to EHR data for the duration of the study.
Exclusion Criteria:
- have prior ischemic or hemorrhagic stroke(s) with an inability to independently perform any one or more basic activities of daily living (ADLs) (i.e., walking, transferring, eating, bathing, dressing, or toileting). (Note: mixed dementias with amyloid pathology are permitted)
- have current or recent serious or unstable illness (other than AD) that, in the investigator's opinion, could interfere with the ability of the participant or study partner to complete the study (e.g., life expectancy of less than 36 months, requirement for long-term (>12 months) institutional-level care, serious psychiatric illness, etc.)
- are currently enrolled or intend to enroll in a clinical trial of another investigational product, and
- have contraindications to donanemab, magnetic resonance imaging (MRI), or amyloid PET tracers. (Donanemab group only).
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Donanemab Group + Usual Care
Participants will receive open-label (unblinded) donanemab intravenously (IV) and Usual Care |
Administered IV
Andra namn:
Medication (excluding amyloid-targeting agents) or non-pharmacological therapy including watchful waiting. |
|
Usual Care Group
Participants will receive usual care. |
Medication (excluding amyloid-targeting agents) or non-pharmacological therapy including watchful waiting. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Time to First Increase in Dependence Level Above Baseline (as derived from the Dependence Scale [DS])
Tidsram: Up to 5 Years
|
The DS is a caregiver-reported outcome assessing the need for daily in-home or institutional assistance by participants with AD. The DS is completed as a structured interview with a knowledgeable caregiver or study partner. The scale is composed of 13 items evaluating progressive needs for assistance. The total score ranges from 0 to 15, with higher scores indicating a greater degree of dependence on external support. |
Up to 5 Years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Tid till förlust av oberoende (beroendenivå ≥3 som härlett från DS) för undergruppen av deltagare med beroendenivå <3 vid baslinjen
Tidsram: Upp till 5 år
|
Upp till 5 år
|
|
|
Ändring från baslinje över tid (halvårsvis) i DS totalresultat
Tidsram: Baslinje, upp till 5 år
|
Baslinje, upp till 5 år
|
|
|
Förändring från baslinje över tid (bedöms halvårsvis) inom hemsjukvård enligt P-LSQ
Tidsram: Baslinje, upp till 5 år
|
Baslinje, upp till 5 år
|
|
|
Ändring från baslinje över tid (bedöms halvårsvis) i körstatus som bedöms av P-LSQ
Tidsram: Baslinje, upp till 5 år
|
Baslinje, upp till 5 år
|
|
|
Time to Institutionalization from Baseline for the Subgroup of Participants not Institutionalized at Baseline
Tidsram: Up to 5 Years
|
Participants who endorse, "Assisted living facility" or "Skilled nursing facility, nursing home, hospice" as their primary residence on the participant lifestyle status Questionnaire (P-LSQ) will be considered institutionalized. |
Up to 5 Years
|
|
Change from Baseline Over Time (Assessed Semi-Annually) in Functional Assessment Questionnaire (FAQ) Total Score
Tidsram: Baseline, Up to 5 Years
|
The FAQ is a brief, 10-item caregiver-reported outcome measure assessing performance on functional activities impacted early during AD. The maximum total score is 30, with higher scores indicating greater impairment. |
Baseline, Up to 5 Years
|
|
Change from Baseline Over Time (Assessed Yearly) in Neuropsychiatric Inventory (NPI-Q) Total Severity Score
Tidsram: Baseline, Up to 5 Years
|
The NPI-Q is a brief, caregiver-reported assessment of neuropsychiatric symptoms associated with dementia. The NPI-Q yields total scores for Severity and Distress, reflecting the sum of ratings across all domains, with higher scores indicating a greater degree of symptom severity and caregiver distress, respectively. |
Baseline, Up to 5 Years
|
|
Change from Baseline Over Time (Assessed Yearly) in Zarit Burden Inventory-short version (ZBI-12) total score
Tidsram: Baseline, Up to 5 Years
|
ZBI is a caregiver-reported instrument used widely to evaluate caregiver burden associated with AD and other diseases such as multiple sclerosis, congestive heart failure, and cancer. Items on the ZBI-12 assess caregiver stress, time available for self, and the impact of caring on the caregiver's social life. Responses are provided on a 5-point Likert scale (never=0, nearly always=4). The ZBI-12 total score has a range of 0 to 48, with higher scores indicating greater caregiver burden. |
Baseline, Up to 5 Years
|
|
Change from Baseline Over Time (Assessed Semi-Annually) in Living Situation as Assessed by the Participant Lifestyle Questionnaire (P-LSQ)
Tidsram: Baseline, Up to 5 Years
|
The P-LSQ is a brief, sponsor-created questionnaire used to collect supplementary data regarding participants' living environment, home healthcare needs, and driving status that is not captured elsewhere. |
Baseline, Up to 5 Years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 18721
- I5T-MC-AACS (Annan identifierare: Eli Lilly and Company)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Tidsram för IPD-delning
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- CSR
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .